The artificial pancreas in 2016: A digital treatment ecosystem for diabetes

Diabetes Care

Volumn 39, Issue 7, 2016, Pages 1123-1126

  Kovatchev, Boris ^a   Tamborlane, William V ^b   Cefalu, William T ^c   Cobelli, Claudio ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIRAGLUTIDE; PRAMLINTIDE;

ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; CLOSED LOOP CONTROL; CONFERENCE PAPER; DIABETES MELLITUS; DIGITAL TREATMENT ECOSYSTEM; DISEASE COURSE; FEASIBILITY STUDY; FEEDBACK SYSTEM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN PUMP; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PRACTICE GUIDELINE; RISK FACTOR;

EID: 84975797327     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0824     Document Type: Conference Paper

References (48)

1. Cefalu WT, Tamborlane WV. The artificial pancreas: are we there yet? Diabetes Care 2014;37:1182-1183
2. Kudva YC, Carter RE, Cobelli C, Basu R, Basu A. Closed-loop artificial pancreas systems: physiological input to enhance next-generation devices. Diabetes Care 2014;37:1184-1190
3. Schiavon M, Dalla Man C, Kudva YC, Basu A, Cobelli C. Quantitative estimation of insulin sensitivity in type 1 diabetic subjects wearing a sensor-augmented insulin pump. Diabetes Care 2014;37:1216-1223
4. Doyle FJ 3rd, Huyett LM, Lee JB, Zisser HC, Dassau E. Closed-loop artificial pancreas systems: engineering the algorithms. Diabetes Care 2014; 37:1191-1197
5. Beck RW, Raghinaru D, Wadwa RP, Chase HP, Maahs DM, Buckingham BA; In Home Closed Loop Study Group. Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system. Diabetes Care 2014;37:1224-1229
6. Hovorka R, Elleri D, Thabit H, et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 2014;37:1204-1211
7. Kumareswaran K, Thabit H, Leelarathna L, et al. Feasibility of closed-loop insulin delivery in type 2 diabetes: a randomized controlled study. Diabetes Care 2014;37:1198-1203
8. Del Favero S, Bruttomesso D, Di Palma F, et al.; AP@home Consortium. First use ofmodel predictive control in outpatient wearable artificial pancreas. Diabetes Care 2014;37:1212-1215
9. Dolgin E. Medical devices: managed by machine. Nature 2012;485:S6-S8
10. Clery D. Medicine. A pancreas in a box. Science 2014;343:133-135
11. Hampton T. Fully automated artificial pancreas finally within reach. JAMA 2014;311: 2260-2261
12. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013;368: 824-833
13. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014;371:313-325
14. Thabit H, Tauschmann M, Allen JM, et al.; APCam Consortium; AP@home Consortium. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2015;373:2129-2140
15. Kropff J, Del Favero S, Place J, et al.; AP@home Consortium. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol 2015;3:939-947
16. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W. An artificial endocrine pancreas. Diabetes 1974;23:389-396
17. Mirouze J, Selam JL, Pham TC, Cavadore D. Evaluation of exogenous insulin homoeostasis by the artificial pancreas in insulin-dependent diabetes. Diabetologia 1977;13:273-278
18. Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ 1978;1:204-207
19. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979;300:573-578
20. Hirsch IB, Armstrong D, Bergenstal RM, et al. Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM). Diabetes Technol Ther 2008;10:232-244; quiz 245-246
21. Tamborlane WV, Beck RW, Bode BW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-1476
22. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006;55:3344-3350
23. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiauto-mated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31:934-939
24. Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol 2010;4:1374-1381
25. Atlas E, Nimri R, Miller S, Grunberg EA, Phillip M. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 2010;33:1072-1076
26. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010;2:27ra27
27. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011; 342:d1855
28. Breton M, Farret A, Bruttomesso D, et al.; International Artificial Pancreas Study Group. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 2012; 61:2230-2237
29. Luijf YM, DeVries JH, Zwinderman K, et al.; AP@home Consortium. Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management. Diabetes Care 2013;36:3882-3887
30. Zisser H, Renard E, Kovatchev B, et al.; Control to Range Study Group. Multicenter closed-loop insulin delivery study points to challenges for keeping blood glucose in a safe range by a control algorithm in adults and adolescents with type 1 diabetes from various sites [published correction appears in Diabetes Technol Ther 2015;17:68]. Diabetes Technol Ther 2014;16:613-622
31. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes 2011; 60:2672-2682
32. Bergenstal RM, Klonoff DC, Garg SK, et al.; ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hy-poglycemia. N Engl J Med 2013;369:224-232
33. Thabit H, Lubina-Solomon A, Stadler M, et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol 2014;2:701-709
34. Keith-Hynes P, Mize B, Robert A, Place J. The Diabetes Assistant: a smartphone-based system for real-time control of blood glucose. Electronics 2014;3:609-623
35. Cobelli C, Renard E, Kovatchev BP, et al. Pilot studies of wearable outpatient artificial pancreas in type 1 diabetes. Diabetes Care 2012;35:e65-e67
36. Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care 2013;36:1851-1858
37. Kovatchev BP, Renard E, Cobelli C, et al. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 2014;37:1789-1796
38. Ly TT, Breton MD, Keith-Hynes P, et al. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care 2014;37:2310-2316
39. Brown SA, Kovatchev BP, Breton MD, et al. Multinight "bedside" closed-loop control for patients with type 1 diabetes. Diabetes Technol Ther 2015;17:203-209
40. Del Favero S, Place J, Kropff J, et al.; AP@home Consortium. Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes. Diabetes Obes Metab 2015;17:468-476
41. Anderson SM, Raghinaru D, Pinsker JE, et al.; Control to Range Study Group. Multinational home use of closed-loop control is safe and effective. Diabetes Care 2016;39:1143-1150
42. Renard E, Farret A, Kropff J, et al.; AP@home Consortium. Day-and-night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: results of a single-arm, 1-month experience compared with a previously reported feasibility study of evening and night at home. Diabetes Care 2016;39:1151-1160
43. Tauschmann M., Allen JM, Wilinska ME, et al. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 2016;39:1168-1174
44. Del Favero S, Boscari F, Messori M, et al. Randomized summer camp crossover trial in 5-to 9-year-old children: outpatient wearable artificial pancreas is feasible and safe. Diabetes Care 2016;39:1180-1185
45. Sherr JL, Patel NS, Michaud CI, et al. Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and liraglutide. Diabetes Care 2016; 39:1127-1134
46. Pinsker JE, Lee JB, Dassau E, et al. Randomized crossover comparison of personalized MPC and PID control algorithms for the artificial pancreas. Diabetes Care 2016;39:1135-1142
47. Maahs DM, Buckingham BA, Castle JR, et al. Outcome measures for artificial pancreas clinical trials: a consensus report. Diabetes Care 2016; 39:1175-1179
48. Russell SJ, Beck RW. Design considerations for artificial pancreas pivotal studies. Diabetes Care 2016;39:1161-1167